about
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisUnresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites.Mapping of a Leishmania major gene/locus that confers pentamidine resistance by deletion and insertion of transposable element.2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities.Association of liposome-encapsulated trivalent antimonial with ascorbic acid: an effective and safe strategy in the treatment of experimental visceral leishmaniasis.Quantitative nucleic acid sequence-based assay as a new molecular tool for detection and quantification of Leishmania parasites in skin biopsy samples.Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification.The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesisP-glycoprotein A Gene Expression in Glucantime-Resistant and Sensitive Leishmania major (MRHO/IR/75/ER)Antimony resistance in leishmania, focusing on experimental research.Leishmania is not prone to develop resistance to tamoxifen.Applications of molecular methods for Leishmania control.Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice.Leishmania antimony resistance: what we know what we can learn from the field.Evaluating drug resistance in visceral leishmaniasis: the challenges.Aurapten, a coumarin with growth inhibition against Leishmania major promastigotes.Essential gene identification and drug target prioritization in Leishmania species.16alpha-Hydroxycleroda-3,13 (14)Z-dien-15,16-olide from Polyalthia longifolia: a safe and orally active antileishmanial agent.Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells.In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells.Effect of topical Nanoliposomes of Paromomycin on Rats Liver and Kidney.Purine nucleobase transport in amastigotes of Leishmania mexicana: involvement in allopurinol uptakeEvaluation of Correlation between the In Vitro Susceptibility of Field Isolates of Leishmania major and Clinical Outcomes of Meglumine Antimoniate Therapy in Fars Province, Iran.Leishmaniasis in humans: drug or vaccine therapy?In Vitro Sensitivity of Cutaneous Leishmania Promastigote Isolates Circulating in French Guiana to a Set of Drugs.A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death.Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.
P2860
Q28271849-A94C208E-DA41-404E-BC25-678F0FBFFDEDQ28468760-1AEE6B6A-8DBA-49A3-A6A9-C2BD06419A87Q31061018-D4EC9E92-27D9-4C46-BD55-6A5B8C79522CQ33294205-DA63E1C6-7CB9-487E-BB14-C5EE1C4F9DEEQ34020450-92B3A645-2752-4782-992C-6DBB69EA02B7Q34143684-EE0AAEF5-F2D1-4A54-9EE8-6F6B621BCFB7Q34763371-3DFFF4E2-A24A-4939-A929-615D4B2FAAE3Q34776421-84C600A0-7F7C-4279-AEA0-AD2C81E785E9Q34940857-72CBD972-66D8-44C6-963D-F573ADB2C22AQ35047361-AB0320DB-9964-4F7C-95E9-1BC29923FF2BQ35607561-B9A84626-856D-4E9C-895C-18EF03DC483EQ35801671-0D3C8DB4-23A7-4356-BEAD-6444A945E02BQ36099396-74481602-2F1E-4378-9B88-FFA5805F00DCQ37204262-80C61B04-5CC2-4CCC-8BF6-1EA296469CECQ37907925-43C38E42-A548-49AA-8C68-FACFBF43FB84Q39014583-7F27612E-CAAD-4FFA-B1F0-C7254506F0B0Q39293708-EDF00FD8-16FF-4959-AF34-19BA2536C245Q39343644-D156E38D-444D-4204-9FA1-6BAE2B36CDC9Q39640638-CAEC21E7-80CF-4CAB-BED4-AB7D13656B3DQ40640236-E6AD1161-127D-4EDD-A33D-11F69EE75F34Q41844113-F1679E93-90F4-490C-82FB-FF3273515E54Q41901399-602AE121-F6C3-4CB2-A5D9-59D9B0811A46Q42017028-5BC2E0B9-6216-4B6C-966E-D6EEB7031BF5Q42042666-229946E1-E03B-4DEB-AC4B-61234A43BEFFQ42277296-3D0D7E29-D0AF-48D3-B5D9-DB483F7D19E1Q47556262-BCB11C27-8A16-472D-81A3-F9E1DBB79D17Q53522202-1C589BC3-6717-4185-BE1D-9AD694D01455Q53592807-38004351-E87B-4D98-ACC0-EC9EEB76B998Q53891579-5FBDDA93-F181-4185-926C-CCD735276902
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Monitoring drug resistance in leishmaniasis.
@ast
Monitoring drug resistance in leishmaniasis.
@en
Monitoring drug resistance in leishmaniasis.
@nl
type
label
Monitoring drug resistance in leishmaniasis.
@ast
Monitoring drug resistance in leishmaniasis.
@en
Monitoring drug resistance in leishmaniasis.
@nl
prefLabel
Monitoring drug resistance in leishmaniasis.
@ast
Monitoring drug resistance in leishmaniasis.
@en
Monitoring drug resistance in leishmaniasis.
@nl
P2860
P1476
Monitoring drug resistance in leishmaniasis.
@en
P2093
P2860
P304
P356
10.1046/J.1365-3156.2001.00754.X
P577
2001-11-01T00:00:00Z